Simcere Zaiming Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting zinc transporter ZIP6 (SLC39A6; LIV-1) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently bound to toll-like receptor 7 (TLR7) and/or toll-like receptor 8 (TLR8) agonist through a linker reported to be useful for the treatment of cancer.
Sevenless Therapeutics Ltd. has patented son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, parkinsonism, neurofibromatosis type 1, atopic dermatitis and cholestasis, among others.
Characteristics of the tumor microenvironment are likely to contribute to the aggressiveness of triple-negative breast cancer (TNBC) and the extremely poor prognosis of those who suffer it. By analyzing patterns of gene expression in cancer-associated fibroblasts from TNBC tumors, researchers in China identified the PLAU gene as a driver of aggressive phenotype.
Immune checkpoint inhibitor therapy has proven effective against many types of solid tumors, but not many subtypes of ovarian cancer, including the rare subtype of ovarian clear cell carcinoma (OCCC). Now, researchers have identified a subtype of OCCC that involves inactivating mutations in the gene PPP2R1A and that responds well to immune checkpoint inhibitor therapy.
Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along with 11 additional programs in development for $500 million up front and up to $12 billion in potential milestones.
Chinese financings are picking up, with Everest Medicines Ltd. raising US$200 million and Nanjing-based Leads Bioloabs Co. Ltd. listing on the main board of the Hong Kong Stock Exchange in a $189 million IPO.
Amplia Therapeutics Ltd. is raising AU$27.5 million (US$18.12 million) to advance lead compound narmafotinib (AMP-945), a focal adhesion kinase (FAK) inhibitor, into new indications beyond pancreatic cancer.
Radiopharma Clarity Pharmaceuticals Ltd. raised AU$203 million (US$132.22 million) in an institutional placement on Australia’s Securities Exchange to advance its late-stage pipeline of copper-based radiopharmaceuticals.
RSS
